Medical NewsGerman Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
| Drug class description : | Anticholinesterases (cholinomimetics). |
| Generic Name : | Galantamine |
| Drug description : | 4mg, off-white tablets; 8mg, pink tablets; 12mg orange-brown tablets. All circular, biconvex tablets marked 'Janssen' on one side and 'G4', 'G8' or 'G12', respectively, on the other side. |
| Presentation : | Tablets, galantamine (as hydrobromide) 4mg , 8mg , 12mg . |
| Indications : | Symptomatic treatment of mild to moderately severe dementia of the Alzheimers type. |
| Adult Dosage : | Recommended starting dose, 4mg twice daily for four weeks. Initial maintenance dose, 8mg twice daily for at least four weeks; increase to 12mg twice daily if required. Maintenance treatment can be continued for as long as therapeutic benefit for the patient exists. |
| Child Dosage : | Not recommended. |
| Contra Indications : | Known hypersensitivity to galantamine hydrobromide or to galantamine hydrobromide or to any excipients used in formulations. Since no data are available on the use of galantamine in patients with severe hepatic impairment (Child- Pugh score greater than 9) and severe renal impairment (creatinine clearance <9mL/ minute), galantamine is contraindicated in these populations. Patients who have both significant hepatic and renal dysfunction. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take galantamine. Lactation. |
| Special Precautions : | A diagnosis of Alzheimer's dementia should be made according to current guidelines by an experienced physician. Therapy should be under physician supervision and should only be initiated if there is a caregiver who can regularly monitor drug intake by the patient. Monitor patient's weight during therapy. Cardiovascular conditions (eg, sick sinus syndrome). History of, or predisposition to peptic ulcer, gastrointestinal obstruction, patients recovering from gastrointestinal surgery. Severe asthma or obstructive pulmonary disease. Urinary outflow obstruction, patients recovering from bladder surgery. Moderate hepatic impairment. Pregnancy. |
| Interactions : | Other cholinomimetics, drugs that significantly decrease heart rate (eg, digoxin and beta-blockers), may enhance succinylcholine-type muscle relaxation during anaesthesia, inhibitors of CYP3A4 (eg, ketoconazole, erythromycin, ritonavir), CYP2D6 inhibitors (eg, quinidine, paroxetine, fluoxetine or fluvoxamine). |
| Adverse Reactions : | Nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, anorexia, fatigue, dizziness, headache, somnolence, weight decrease, confusion, fall, injury, insomnia, rhinitis, syncope and severe bradycardia have also been reported. |
| Manufacturer : | Shire |
| Drug Availability : | (POM) |
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org